Drug General Information (ID: DDITAXOEQN)
Drug Name			Thalidomide		Drug Info		Durvalumab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Immunosuppressive Agents				Antineoplastics

Mechanism of Thalidomide-Durvalumab Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Thalidomide				Durvalumab
Mechanism		Thalidomide analogs				Increased risk of mortality in multiple myeloma patients treated with thalidomide or its analogs
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Thalidomide and Durvalumab

Recommended Action
Management		Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.

References
1	Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
2	Product Information. Keytruda (pembrolizumab). Merck &amp Company Inc, Whitehouse Station, NJ.
3	Product Information. Revlimid (lenalidomide). Celgene Corporation, Summit, NJ.